The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with

Humans Positron Emission Tomography Computed Tomography Retrospective Studies Positron-Emission Tomography Neuroendocrine Tumors / diagnostic imaging Organometallic Compounds / therapeutic use Pancreatic Neoplasms Octreotide / therapeutic use
177Lu DOTATATE (LuTate) therapy Gastro-entero-pancreatic neuroendocrine neoplasm GEP NEN Peptide Receptor Radionuclide Therapy (PRRT) Radiopharmaceutical Dosimetry Radiosensitising Chemotherapy

Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
08 2023
Historique:
received: 03 12 2022
accepted: 30 04 2023
medline: 31 7 2023
pubmed: 15 5 2023
entrez: 15 5 2023
Statut: ppublish

Résumé

Peptide Receptor Radionuclide Therapy (PRRT) delivers targeted radiation to Somatostatin Receptor (SSR) expressing Neuroendocrine Neoplasms (NEN). We sought to assess the predictive and prognostic implications of tumour dosimetry with respect to response by Patients with gastro-entero-pancreatic (GEP) NEN who received LuTate followed by quantitative SPECT/CT (Q-SPECT/CT) the next day (Jul 2010 to Jan 2019) were retrospectively reviewed. Single time-point (STP) lesional dosimetry was performed for each cycle using population-based pharmacokinetic modelling. MITV Median of 4 PRRT cycles were administered to 90 patients (range 2-5 cycles; mean 27.4 GBq cumulative activity; mean 7.6 GBq per cycle). 68% received at least one cycle with radiosensitising chemotherapy (RSC). RECIST 1.1 partial response was 24%, with 70% stable and 7% progressive disease. Cycle 1 radiation dose in measurable lesions was associated with local response (odds ratio 1.5 per 50 Gy [95% CI: 1.1-2.0], p = 0.002) when adjusted by tumour grade and RSC. Median change in MITV Radiation dose to tumour during PRRT was predictive of radiologic response but not survival. Survival outcomes may relate to other biological factors. There was no evidence that MITV

Identifiants

DOI: 10.1007/s00259-023-06257-6 PMID: 37184682 PMC: PMC10382388
pubmed: 37184682
doi: 10.1007/s00259-023-06257-6
pii: 10.1007/s00259-023-06257-6
pmc: PMC10382388
doi:

Substances chimiques

copper dotatate CU-64 0
Organometallic Compounds 0
Octreotide RWM8CCW8GP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2997-3010

Informations de copyright

© 2023. The Author(s).

Références

Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):5-19
pubmed: 25273832
J Nucl Med. 2021 Dec;62(Suppl 3):12S-22S
pubmed: 34857617
Neuroendocrinology. 2017 Apr 13;105(3):295-309
pubmed: 28402980
J Nucl Med. 2015 Feb;56(2):177-82
pubmed: 25593115
J Nucl Med. 2020 Jul;61(7):1030-1036
pubmed: 31806772
J Nucl Med. 2018 Mar;59(3):452-458
pubmed: 28775205
Med Phys. 2013 Nov;40(11):112503
pubmed: 24320462
Cancers (Basel). 2021 Feb 25;13(5):
pubmed: 33668887
J Clin Oncol. 2008 May 1;26(13):2124-30
pubmed: 18445841
Ann N Y Acad Sci. 1994 Sep 15;733:496-506
pubmed: 7978900
J Nucl Med. 1993 Oct;34(10):1632-8
pubmed: 8410273
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):718-727
pubmed: 30343432
Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1853-60
pubmed: 23864305
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1802-11
pubmed: 27160225
J Nucl Med. 2018 Jan;59(1):75-81
pubmed: 28588150
Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2125-35
pubmed: 21892623
Med Phys. 2018 May;45(5):2318-2324
pubmed: 29577338
Sci Rep. 2020 Jun 23;10(1):10196
pubmed: 32576907
Endocrine. 2017 Nov;58(2):368-379
pubmed: 28303513
Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1831-44
pubmed: 24844348
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):970-988
pubmed: 29497803
Cancer Imaging. 2011 Jun 15;11:56-66
pubmed: 21684829
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):728-742
pubmed: 30506283
J Nucl Med. 2014 Feb;55(2):183-90
pubmed: 24434296
J Nucl Med. 2019 Jun;60(6):777-785
pubmed: 30442752
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Phys Med Biol. 2022 Jan 19;67(2):
pubmed: 34965519
J Nucl Med. 2021 Aug 1;62(8):1118-1125
pubmed: 33443063
Endocr Relat Cancer. 2015 Aug;22(4):657-64
pubmed: 26113608
Eur J Nucl Med Mol Imaging. 2014 May;41(5):925-33
pubmed: 24504504
J Nucl Med. 2005 Jan;46 Suppl 1:92S-8S
pubmed: 15653657
Ann Oncol. 1999;10 Suppl 2:S23-9
pubmed: 10399029
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1902-1910
pubmed: 31187162

Auteurs

R Alipour (R)

Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia. Ramin.Alipour@petermac.org.
The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia. Ramin.Alipour@petermac.org.
ORCID: 0000-0002-1248-0967

P Jackson (P)

Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.

M Bressel (M)

The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia.

A Hogg (A)

Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.

J Callahan (J)

Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.

R J Hicks (RJ)

Department of Medicine, St Vincent's Medical School, The University of Melbourne, Melbourne, Australia.

G Kong (G)

Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia.
The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The relationship between tumour dosimetry,...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › The relationship between tumour dosimetry,...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › The relationship between tumour dosimetry,...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › The relationship between tumour dosimetry,...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroendocrines › The relationship between tumour dosimetry,...
questionsmedicales.fr › Composés chimiques organiques › Composés organométalliques › The relationship between tumour dosimetry,...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › The relationship between tumour dosimetry,...
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Peptides cycliques › Octréotide › The relationship between tumour dosimetry,...